Basilard Team
Company Board of Directors and Management Team
Bradley Glover, Board Member
Dr. Bradley Glover is an accomplished biotechnology executive with more than 25 years of experience in biotechnology, pharmaceuticals, and life sciences. His leadership expertise spans cell and gene therapy, corporate strategy, business development, capital formation, and the advancement of innovative technologies from early-stage development through commercialization.
Dr. Glover previously served as Chief Operating Officer at GNI Medtech and Imugene Ltd (ASX: IMU), and as Executive Vice President and Chief Operating Officer of Celularity, where he led strategic, operational, and corporate development initiatives. At Kite Pharma, he served as Vice President of Corporate Development and Head of Corporate Strategy, as well as Vice President of Technical Operations Strategy, contributing to the development and commercialization of pioneering CAR-T therapies, including YESCARTA® and TECARTUS™. Earlier in his career, he held leadership positions at Genentech, Roche, and Illumina.
Throughout his career, Dr. Glover has led strategic partnerships, licensing transactions, acquisitions, financing initiatives, and the development of global manufacturing and commercial infrastructure. He previously served as Chairman of Chimeric Therapeutics and has extensive experience advising and building emerging biotechnology companies.
Dr. Glover holds a PhD in Biochemistry and Molecular Genetics from the University of Colorado and an MBA from the University of California, San Diego. He completed postdoctoral research at the University of California, Berkeley.
Paul Conley, Board Member
Dr. Paul Conley is the Preferred Stock representative on the Board of Directors of Basilard BioTech.
Paul has 15 years of operating experience, including as founding CEO of Brightside and Appfluent Technology. Before that he spent six years at Los Alamos National Labs leading doctoral and post-doctoral research projects in the computational modeling of high explosive materials and components.
Since 2007, Paul has been a venture capital investor (Paladin Capital, Vertical Venture Partners, General Inception, et. al.) in early stage technology and biotech companies, leveraging his scientific and operating experience to help them succeed and grow.
Dr. Conley has a PhD in Computational Physics from UC San Diego.
Nuné Martiros, Board Member
Dr. Nuné Martiros works on sourcing and assessing investments for the Digital Biology fund at Paladin Capital, including interfacing with Paladin-founded venture studio General Inception. She previously worked on developing and assessing early stage biotechnology companies at Foresite Labs and was a Fellow at Flagship Pioneering. Nuné completed her undergraduate studies and doctoral thesis research in neuroscience at MIT and postdoctoral research at Harvard University.
Her research focused on using electrophysiology and multiphoton imaging to study the real-time activity of basal ganglia neuronal populations, the role of dopamine signaling, and olfactory sensory input.
Dr. Martiros is the lead author on multiple research publications in scientific journals and has been the recipient of multiple research grants from the NIH.
She has a particular focus on sourcing investments from the active Boston biotechnology innovation ecosystem.
Sammy Datwani, Board Member
Dr. Sammy S. Datwani is the Vice President of Development at Synthego.
He has previously been Head of Technology Development at Inscripta, Sr. Director of R&D and Principal Scientist at Labcyte (Beckman Coulter Life Sciences) and was also at Eksigent Technologies and Caliper Life Sciences.
His career focus has been on the development of emergent life sciences technologies, particularly revolutionary biotech tools and microfluidics-based instruments. Sammy serves on the Board of Directors for the Life Science Angels, the Society of Laboratory Automation & Screening (SLAS) and the Johns Hopkins University School of Engineering.
Dr. Datwani was inducted to the College of Fellows of the American Institute of Medical and Biological Engineers (AIMBE). He received his Ph.D. in Chemical & Biomolecular Engineering from Johns Hopkins University.
Lynne R. Rollins, CFO
Lynne Rollins has over 45 years of experience in the healthcare industry in the areas of finance and business development. She was with Baxter Healthcare Corporation for 19 years; her positions there included Vice President of Business Development for the Cardiopulmonary Business of the CardioVascular Group and Vice President of Finance for the Cardiopulmonary Business, Bentley Division.
More recently she has had her own consulting business as a CFO consultant for start-up pharmaceutical and medical device companies. She has consulted for 49 pharmaceutical and medical device companies in the role of CFO over the last 24 years.
She received her Bachelor’s Degree in Finance from California State University and her MBA from Pepperdine University.
Faysal Ahmed, Development Engineering Advisor
Faysal Ahmed leads Engineering and Systems Development at Basilard BioTech, overseeing the design, integration, and scale-up of the Celletto technology for non-viral, ex vivo gene delivery. He directs the development of the integrated fluidic systems and supporting instrumentation that enable Celletto’s MEMS- based technology, transforming core microfluidic capabilities into functional, scalable platforms. He leads current and next-generation prototype development, aligning engineering strategy with the evolving needs of cell and gene therapy industry partners.
His career has focused on the development and commercialization of innovative medical devices and life science technologies, with particular expertise in microfluidics, systems engineering, and complex fluidic instrumentation. He has successfully contributed to advancing multiple medical devices through the FDA regulatory process and into commercial use, bringing extensive experience in product development, system integration, and manufacturing scale-up.
Prior to Basilard BioTech, Faysal held engineering positions at Adagio Medical, Masimo, Replenish, and Celula, and contributed to research at Northwestern University. He holds an M.S. in Biomedical Engineering from the New Jersey Institute of Technology.
Dennis Yost, MEMS Development Advisor
Dennis Yost has 30+ years of semiconductor and MEMS industry experience, including at Texas Instruments, Applied Materials and Novellus Systems. As CEO of Cavendish Kinetics, he moved the company from an R&D focus to producing the first high volume qualified MEMS variable capacitors for cell phone applications.
He was recently CEO of Deca Technologies leading the company’s introduction of revolutionary wafer level chip scale packaging (M-Series) and transition from a manufacturing to an IP business.
Dennis has authored multiple papers and holds multiple patents in semiconductor device technology and MEMS. He received his MBA from Southern Methodist University.
Jon Ellis, Cell Therapy Process Development Advisor
Jon Ellis brings over 20 years of experience in cell therapy technology and process development to
Basilard BioTech. His background is in GMP manufacturing, development and implementation of new
technologies from feasibility testing through to commercial launch, and the automation of cell therapy
processes.
He has held these roles in national healthcare systems, multinational consultancy firms and pioneering start-ups and is currently Chief Executive Officer at Trenchant BioSystems Inc.
He has deep familiarity with Basilard’s Celletto technology and is an active advisor to the company, helping to chart our commercial path.